JAK inhibitors are the newest class — powerful, and uniquely oral rather than injected. They work brilliantly for many, but they carry a genuine safety debate that every user should understand before starting.
JAK inhibitors (tofacitinib/Xeljanz, baricitinib/Olumiant, upadacitinib/Rinvoq, filgotinib) block immune signalling inside the cell, and they're taken as a daily pill — a big convenience over injected biologics. They're highly effective; upadacitinib in particular beat an established biologic head-to-head. Evidence ●●●●○
The honest caveat: a large safety trial (ORAL Surveillance) compared a JAK inhibitor against a TNF biologic specifically in higher-risk patients (over 50 with a heart-risk factor) and found more heart attacks and strokes, blood clots, cancers, and deaths — leading the FDA to add boxed warnings across the class and restrict them to use after a TNF blocker has failed. The balancing truth: the trial studied an enriched, higher-risk group, and in a younger, lower-risk person who wants an oral drug, JAK inhibitors remain very useful. The risk-benefit is individual, not a blanket 'avoid.' Evidence ●●●●○
A genuinely personalised call
For a younger person with few cardiovascular risk factors, a JAK inhibitor can be an excellent oral option; for someone older or with heart-disease or clot risk, guidelines steer toward a biologic instead. Weigh it with your rheumatologist against your own risk profile — not the headline alone.
The RA Guide